Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adamis, Advancell, Astellas, DMK, Erytech, Inveric, Pahxiam, Pherecydes, Point, TFF, Tonix, Ubsher-Smith.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akero, Aslan, Gilead, Hifibio, Intercept, Sagimet, Sumitomo.

Biopharmas raising money in public or private financings, including: Acer, Actimed, Diamedica, Orchard, Oric.

New hires and promotions in the biopharma industry, including: ABVC, Kallyope, Uniqure.

The top 10 biopharma stock gainers and losers for the week.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alzamend, Aptorum, Biocity, Compugen, Horizon, Hyloris, Ideaya, Inhibikase, Inmed, Invivyd, Jasper, Madrigal, Memo, Palleon, Reviva, Roivant, Seelos, Sellas, Tvardi, Vaxxinity.

Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Atyr, Cidara, GSK, Kite, Kymera, Mindset.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acasti, Bavarian, Cimeio, Nephrodi, Prime, Zucara.